SPYH:F:F-SSgA SPDR ETFs Europe II Public Limited Company - SPDR MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 212.9

Change

+1.65 (+0.78)%

Market Cap

N/A

Volume

4.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.13 (-0.47%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.29 (-0.54%)

USD 116.19B
SXR8:F iShares Core S&P 500 UCITS ETF..

-3.84 (-0.63%)

USD 109.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.31 (-0.53%)

USD 98.97B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.08 (-0.51%)

USD 63.27B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.20 (+0.08%)

USD 52.42B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.70 (-0.63%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.37 (+0.34%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 38.52B
0ZC:F Zscaler Inc

-2.56 (-1.40%)

USD 37.92B

ETFs Containing SPYH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.37% 26% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.37% 26% F 38% F
Trailing 12 Months  
Capital Gain 2.13% 30% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.13% 27% F 41% F
Trailing 5 Years  
Capital Gain 32.43% 63% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.43% 62% D 47% F
Average Annual (5 Year Horizon)  
Capital Gain 9.18% 67% D+ 64% D
Dividend Return 9.18% 64% D 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.28% 74% C 93% A
Risk Adjusted Return 110.97% 97% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike